Get the Stockscreener App
140.61
3.21%
-4.66
After Hours:
140.70
0.09
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $140.61, with a volume of 13.08M.
It is down -3.21% in the last 24 hours and down -5.49% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$145.27
Open:
$145.89
24h Volume:
13.08M
Relative Volume:
1.16
Market Cap:
$346.91B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
39.57
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
-2.10%
1M Performance:
-5.49%
6M Performance:
+25.66%
1Y Performance:
+60.72%
1-Day Range:
$139.93
$146.61
1-Week Range:
$139.93
$154.02
52-Week Range:
$82.01
$156.92
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
140.61 | 346.91B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,279.14 | 1.14T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.30 | 641.07B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
286.74 | 506.70B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
153.81 | 292.35B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-20-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-26 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-06-26 | Resumed | Citigroup | Neutral |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? - The Motley Fool
Breakfast News: Science Strikes Back at Cancer - The Motley Fool
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now? - Zacks Investment Research
Microbiotica Presents Phase 1b Clinical Data on MB097 at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewswire Inc.
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? - The Motley Fool
Breakfast News: A Conversation With Moderna’s CEO - The Motley Fool
Moderna’s Stock Just Stumbled. Is It a Buy on the Dip? - The Motley Fool
Why Healthcare ETFs Are Hovering Around One-Year Highs - Zacks Investment Research
Moderna, Merck Shares Fall After Possible Melanoma Data Leak - Bloomberg.com
Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports - The Motley Fool
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat - Reuters
Merck & Co Inc Stock (MRK) Moved Down by 3.28% on Oct 22: A Full Analysis - TradingKey
Summit Expands Ivonescimab Development Into Biliary Tract Cancer - Zacks Investment Research
Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline - Zacks Investment Research
6,761 Merck & Co., Inc. $MRK Shares Sold by Smith Chas P & Associates PA Cpas - MarketBeat
Merck & Co., Inc. $MRK Stock Sold by Inlet Private Wealth LLC - MarketBeat
Merck & Co., Inc. $MRK Stock Sold by Crossmark Global Holdings Inc. - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Diversify Advisory Services LLC - MarketBeat
Merck & Co., Inc. (MRK) Set to Release Earnings on Thursday - MarketBeat
Merck & Co., Inc. $MRK Stock Holdings Lowered by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat
27,739 Merck & Co., Inc. $MRK Shares Sold by Axxcess Wealth Management LLC - MarketBeat
Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight - GlobeNewswire Inc.
Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 - The Motley Fool
Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio? - Zacks Investment Research
Merck & Co., Inc. (NYSE:MRK) Cut to "Strong Sell" at Zacks Research - MarketBeat
6,860 Merck & Co., Inc. $MRK Shares Sold by QV Investors Inc. - MarketBeat
119,254 Merck & Co., Inc. $MRK Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Merck & Co., Inc. $MRK Stock Sold by Nisa Investment Advisors LLC - MarketBeat
Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice - The Motley Fool
Bank Pictet & Cie Europe AG Sells 42,242 Shares of Merck & Co., Inc. $MRK - MarketBeat
Why Are Market Participants Following Merck & Co. (NYSE:MRK)? - Kalkine Media
Lobbying Update: $2,390,000 of MERCK & CO INC lobbying was just disclosed - Quiver Quantitative
Is Merck & Co Inc (MRK) Overvalued After 3.2% Rally? GF Value Sa - GuruFocus
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million - GlobeNewswire Inc.
Net current asset value per share of Merck & Co., Inc. Shs Thailand Depositary Receipts Repr 1 Sh – SET:MRK03 - TradingView
Catholic Medical Mission Board and Church of the Brethren to mark partnership with ribbon-cutting - GlobeNewswire Inc.
Merck & Co., Inc. $MRK Stock: Willis Investment Counsel Cuts Holdings - MarketBeat
Merck (MRK) Has New Cancer Treatments. Can They Outgrow the Keytruda Patent Cliff? - Yahoo Finance
Merck Discontinues Bacterial Infection Drug in Europe - Benzinga
Merck & Co Inc Stock (MRK) Opened Up by 3.79% on Oct 20: What Signal Does It Send? - TradingKey
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Merck (NYSE:MRK) Nears Breakout Setup With Strong Technical Ratings - ChartMill
64,996 Merck & Co., Inc. $MRK Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
Merck’s 2.4% Dividend Yield: A Reliable Income Stream or a Risky Bet on Recovery? - Yahoo Finance
Merck & Co., Inc. $MRK Position Boosted by Fairvoy Private Wealth LLC - MarketBeat
Merck (MRK) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
13,487 Merck & Co., Inc. $MRK Shares Sold by Generali Investments Management Co LLC - MarketBeat
MERCK & CO INC : HSBC RAISES TARGET PRICE TO $175 FROM $172 - Moomoo
Merck & Company, Inc. (MRK) Stock Forecasts - Yahoo Finance
Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors. - The Motley Fool
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merck Co Inc Stock (MRK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| CHIRFI GUINDO | Officer |
Aug 13 '26 |
Proposed Sale |
135.00 |
10,000 |
1,350,000 |
0 |
| JENNIFER L ZACHARY | Officer |
Aug 12 '26 |
Proposed Sale |
133.46 |
80,315 |
10,718,495 |
0 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 12 '26 |
Proposed Sale |
131.63 |
11,699 |
1,539,992 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 12 '26 |
Sale |
131.63 |
11,699 |
1,539,992 |
110,167 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Option Exercise |
109.78 |
54,927 |
6,029,637 |
125,824 |
| Zachary Jennifer | EVP, General Counsel |
Aug 12 '26 |
Sale |
133.46 |
80,315 |
10,718,495 |
45,509 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 11 '26 |
Sale |
131.76 |
12,837 |
1,691,426 |
121,866 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 11 '26 |
Proposed Sale |
131.76 |
12,837 |
1,691,426 |
0 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth |
Aug 10 '26 |
Sale |
130.43 |
20,784 |
2,710,951 |
134,703 |
| RICHARD ROBERT DELUCA JR | Officer |
Aug 10 '26 |
Proposed Sale |
130.43 |
20,784 |
2,710,951 |
0 |
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):